CAR-T cell therapy market - Non-Hodgkin Lymphoma

View All

chimeric-antigen-receptor-therapies-in-blood-cancers
A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers

Chimeric Antigen Receptor (CAR) Therapies have changed the treatment paradigm of hematological malignancies to a vast extent. These personalized therapies have not only evolved as a game-changer in the field of medicine but also in the lives of the patients. Until the last approvals made by Novartis and Kite Pha...

Find More

CAR-T cell therapy market for Non-Hodgkin lymphoma
CAR-T cell therapy market for Non-Hodgkin lymphoma: Future prospects, and untapped opportunities

As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030. During the course of past decades, with the advancement in technology and a clear understanding of the molecular patho...

Find More